Jiangsu Hengrui Medicine Co., Ltd. (HKG:1276)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
85.40
-0.80 (-0.93%)
Last updated: Sep 8, 2025, 1:08 PM HKT
-0.93%
Market Cap526.09B
Revenue (ttm)33.03B
Net Income (ttm)8.06B
Shares Outn/a
EPS (ttm)1.27
PE Ratio65.28
Forward PE50.70
Dividendn/a
Ex-Dividend Daten/a
Volume1,574,830
Average Volume6,576,988
Open86.95
Previous Close86.20
Day's Range85.15 - 86.95
52-Week Range52.50 - 87.80
Betan/a
RSI59.80
Earnings DateAug 21, 2025

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; tra... [Read more]

Sector Healthcare
Founded 1970
Employees 20,238
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1276
Full Company Profile

Financial Performance

In 2024, Jiangsu Hengrui Medicine's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.